celecoxib has been researched along with Thrombosis in 19 studies
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies." | 9.12 | Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. ( Bingham, CO; Bird, S; Fitzgerald, BJ; Kremer, J; O'Brien, K; Rubin, BR; Ruoff, GE; Sebba, AI; Smugar, SS; Tershakovec, AM, 2007) |
| "To determine whether the cyclooxygenase-2 (COX-2) inhibitor celecoxib affects cardiovascular thrombotic risk, we analyzed the incidence of cardiovascular events for celecoxib, placebo, and nonsteroidal anti-inflammatory drugs (NSAIDs) in the entire controlled, arthritis clinical trial database for celecoxib." | 7.72 | Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. ( Borer, JS; Faich, G; Makuch, RW; White, WB, 2003) |
| "Main parameter was thrombus weight." | 5.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
| "To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies." | 5.12 | Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. ( Bingham, CO; Bird, S; Fitzgerald, BJ; Kremer, J; O'Brien, K; Rubin, BR; Ruoff, GE; Sebba, AI; Smugar, SS; Tershakovec, AM, 2007) |
| "To determine whether the cyclooxygenase-2 (COX-2) inhibitor celecoxib affects cardiovascular thrombotic risk, we analyzed the incidence of cardiovascular events for celecoxib, placebo, and nonsteroidal anti-inflammatory drugs (NSAIDs) in the entire controlled, arthritis clinical trial database for celecoxib." | 3.72 | Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. ( Borer, JS; Faich, G; Makuch, RW; White, WB, 2003) |
| "Rofecoxib was withdrawn from the market on 30 September 2004 following the results of a randomized controlled trial." | 1.35 | Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? ( Bagheri, H; Grolleau, S; Lapeyre-Mestre, M; Montastruc, JL; Sommet, A, 2008) |
| "Main parameter was thrombus weight." | 1.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (78.95) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klapwijk, LC | 1 |
| Mathijssen, NM | 1 |
| Van Egmond, JC | 1 |
| Verbeek, BM | 1 |
| Vehmeijer, SB | 1 |
| Mosaad, SM | 2 |
| Zaitone, SA | 2 |
| Ahmed, AA | 1 |
| Abo-Elmatty, DM | 1 |
| El-Baz, AA | 1 |
| Moustafa, YM | 2 |
| Sommet, A | 1 |
| Grolleau, S | 1 |
| Bagheri, H | 1 |
| Lapeyre-Mestre, M | 1 |
| Montastruc, JL | 1 |
| El-Orabi, NF | 1 |
| White, WB | 1 |
| Faich, G | 1 |
| Borer, JS | 1 |
| Makuch, RW | 1 |
| Umar, A | 1 |
| Boisseau, M | 1 |
| Yusup, A | 1 |
| Upur, H | 1 |
| Bégaud, B | 1 |
| Moore, N | 1 |
| Bannwarth, B | 1 |
| Bingham, CO | 1 |
| Sebba, AI | 1 |
| Rubin, BR | 1 |
| Ruoff, GE | 1 |
| Kremer, J | 1 |
| Bird, S | 1 |
| Smugar, SS | 1 |
| Fitzgerald, BJ | 1 |
| O'Brien, K | 1 |
| Tershakovec, AM | 1 |
| Steffel, J | 1 |
| Akhmedov, A | 1 |
| Fähndrich, C | 1 |
| Ruschitzka, F | 1 |
| Lüscher, TF | 1 |
| Tanner, FC | 1 |
| Mukherjee, D | 2 |
| Sibilia, J | 1 |
| Deray, G | 2 |
| Montalescot, G | 1 |
| Valat, JP | 1 |
| Héloire, F | 1 |
| Zhou, YJ | 1 |
| Xiong, YX | 1 |
| Zhou, T | 1 |
| Fan, W | 1 |
| Wu, XT | 1 |
| Crofford, LJ | 1 |
| Oates, JC | 1 |
| McCune, WJ | 1 |
| Gupta, S | 1 |
| Kaplan, MJ | 1 |
| Catella-Lawson, F | 1 |
| Morrow, JD | 1 |
| McDonagh, KT | 1 |
| Schmaier, AH | 1 |
| McMurray, R | 1 |
| Sperling, R | 1 |
| Braunstein, N | 1 |
| Melin, J | 1 |
| Reicin, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 2)[NCT00092781] | Phase 3 | 500 participants (Actual) | Interventional | 2004-03-01 | Completed | ||
| A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 1)[NCT00092768] | Phase 3 | 500 participants (Actual) | Interventional | 2004-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for celecoxib and Thrombosis
| Article | Year |
|---|---|
Celecoxib safety revisited.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cli | 2016 |
Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 | 2006 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celeco | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.
Topics: Animals; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloox | 2002 |
1 trial available for celecoxib and Thrombosis
13 other studies available for celecoxib and Thrombosis
| Article | Year |
|---|---|
The first 6 weeks of recovery after primary total hip arthroplasty with fast track.
Topics: Acetaminophen; Activities of Daily Living; Adult; Aged; Aged, 80 and over; Ambulatory Surgical Proce | 2017 |
Evening primrose oil or forskolin ameliorates celecoxib-enhanced upregulation of tissue factor expression in mice subjected to lipopolysaccharide-induced endotoxemia.
Topics: Animals; Antithrombin III; Blood Coagulation; Celecoxib; Colforsin; Cyclooxygenase 2 Inhibitors; Dis | 2017 |
Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?
Topics: Adverse Drug Reaction Reporting Systems; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; | 2008 |
Effect of evening primrose oil and ω-3 polyunsaturated fatty acids on the cardiovascular risk of celecoxib in rats.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Celecoxib; Dietary Fats, Unsaturated; Fatty Acids, | 2011 |
Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Humans; Py | 2003 |
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxy | 2004 |
Do selective cyclo-oxygenase-2 inhibitors have a future?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibito | 2005 |
Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Celecoxib; Cell Line; Endothelium, Vascula | 2006 |
[Role of cyclooxygenase-2 in pulmonary microcirculation disorder in rats with acute pancreatitis].
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Gene Expression Regulation; Lung; | 2007 |
Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases.
Topics: Adult; Antibodies, Anticardiolipin; Celecoxib; Connective Tissue Diseases; Cyclooxygenase 2; Cycloox | 2000 |
Cyclooxygenase 2 inhibition and thrombosis: comment on the article by Crofford et al.
Topics: Antiphospholipid Syndrome; Celecoxib; Connective Tissue Diseases; Cyclooxygenase 2; Cyclooxygenase 2 | 2001 |
Cyclooxygenase 2 inhibitors and thrombogenicity production: comment on the article by Crofford et al.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzy | 2001 |
Cardiovascular safety of COX-2 inhibitors.
Topics: Cardiovascular Physiological Phenomena; Celecoxib; Consumer Product Safety; Cyclooxygenase Inhibitor | 2001 |